Traws Pharma, Inc. Deferred Tax Assets, Deferred Income
Traws Pharma, Inc. (TRAW) had Deferred Tax Assets, Deferred Income of $696.00 thousand as of 2024-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2026-04-15
- 2024-12-31: Deferred Tax Assets, Deferred Income $696.00K.
- 2023-12-31: Deferred Tax Assets, Deferred Income $752.00K.
- 2022-12-31: Deferred Tax Assets, Deferred Income $809.00K.
- 2021-12-31: Deferred Tax Assets, Deferred Income $1.00M.
| Period end | Deferred Tax Assets, Deferred Income | Deferred Tax Assets, Deferred Income as first filed |
|---|---|---|
| 2024-12-31 | $696.00K 10-K · filed 2026-04-15 | |
| 2023-12-31 | $752.00K 10-K · filed 2025-03-31 | |
| 2022-12-31 | $809.00K 10-K · filed 2024-04-01 | |
| 2021-12-31 | $1.00M 10-K · filed 2023-03-30 | |
| 2020-12-31 | $1.07M 10-K · filed 2022-03-21 | |
| 2019-12-31 | $1.13M 10-K · filed 2021-03-18 | |
| 2018-12-31 | $1.24M 10-K · filed 2020-03-27 | $1.18M 10-K · filed 2019-04-01 |
| 2017-12-31 | $1.24M 10-K · filed 2019-04-01 | |
| 2016-12-31 | $2.03M 10-K · filed 2018-03-16 | |
| 2015-12-31 | $2.20M 10-K · filed 2017-03-29 | |
| 2014-12-31 | $5.65M 10-K · filed 2016-03-28 | |
| 2013-12-31 | $5.94M 10-K · filed 2015-03-30 | |
| 2012-12-31 | $4.25M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |